1. Huachang Chemical: In February 2020, Nanjing Shihe Gene and Practical Medicine invested by Suzhou Ruihua Investment Partnership (the company holds 10% of the fund share) successfully developed COVID-19 nucleic acid detection kit, which is one of the nucleic acid funds.
2. Health in the United States: In April 2020, the company launched two programs for anti-epidemic screening, among which "novel coronavirus nucleic acid detection program" is one of the nucleic acid funds, with virus nucleic acid detection as the main project.
3. Focusing technology: Yoshida sells portable PCR (portable nucleic acid detection kit), which can be used for novel coronavirus detection and African swine fever monitoring, and is one of the nucleic acid funds.